Investor Relations
Financial Highlights — Q3 2026 (9 Months Ended Sept 30)
NOVUS ACQUISITION & DEVELOPMENT CORP. (OTC: NDEV)
Q3 2025 (Steel Blue) vs. Q3 2026 (Bright Gold) Performance
YoY
YTD
YTD
Year-Over-Year & Year-to-Date Financial Growth
- Gross Revenue: 7.78% year-over-year increase.
- Total Assets: 2.34% year-to-date expansion.
- Stockholders' Equity (Net Book Value): 2.26% year-to-date increase.
Capital Structure & Shareholder Protection
- Insider Share Liquidation: 0% over the trailing 36-month period.
- Debt-to-Equity Ratio: 9.74% (reflecting a highly unleveraged balance sheet).
- Convertible Debt: 0% of total liabilities.
- Vendor Share Leak-Out Provision: 100% active enforcement (capping restricted common stock sales at 15% of the trailing 30-day average daily trading volume).
Operational & Strategic Efficiencies
- Platform Segregation: 100% operational separation between the Prescription Drug Platform and the cannabis-adjacent ordering platform.
- Optimized Tax Arbitrage: 15% to 17% contraction achieved in the effective tax burden for policyholders utilizing the proprietary Rx platform.
- Point-of-Sale Economics: 25% to 30% reduction in gross product costs at the point of sale.
Consolidated Balance Sheet as of September 30, 2026 (Unaudited)
| Novus Acquisition & Development Corp. | 30-Sep-26 ($) | 31-Dec-25 ($) |
|---|---|---|
| ASSETS | ||
| Cash and cash equivalents | 251,443 | 241,912 |
| Investments | 0 | 0 |
| Software Development | 235,344 | 220,678 |
| Insurance Contracts | 490,891 | 468,024 |
| Deferred Tax Loss Carried Forward | 262,352 | 267,420 |
| Insurance Assets | 513,000 | 513,000 |
| Goodwill | 229,374 | 226,097 |
| TOTAL ASSETS | 1,982,404 | 1,937,132 |
| LIABILITIES AND EQUITY | ||
| Note Due to Related Party | 175,941 | 170,577 |
| Deferred Credits and Other Noncurrent Liabilities | 0 | 0 |
| Total current liabilities | 175,941 | 170,577 |
| Common Stock: 200,000,000 shares authorized, $.001 par value (up 2,000,000 since Mar 31, 2026) | 126,803 | 126,803 |
| Series A Preferred: $.001 par value; 6,600 shares authorized, issued, and outstanding | 660 | 660 |
| Series B Preferred dividend stock: $.001 par value; 100,000,000 shares authorized; 0 issued | 0 | 0 |
| Series C & D Preferred Shares: $.001 par value; 100,000,000 shares authorized; 0 issued | 0 | 0 |
| Additional paid-in capital | 8,606,929 | 8,437,767 |
| Accumulated Deficit | -6,800,466 | -6,671,212 |
| Total Equity | 1,806,463 | 1,766,555 |
| Total Liabilities and Equity | 1,982,404 | 1,937,132 |
| Earnings Per Share | $0.0154 | $0.0153 |
Consolidated Income Statement as of September 30, 2026 (Unaudited)
| Novus Acquisition & Development Corp. | 3M Ended 9/30/26 ($) | 3M Ended 9/30/25 ($) | 9M Ended 9/30/26 ($) | 9M Ended 9/30/25 ($) |
|---|---|---|---|---|
| Revenues | 108,982 | 102,347 | 323,380 | 300,044 |
| G&A Expenses | 23,009 | 20,029 | 68,167 | 58,478 |
| Professional fees | 4,800 | 4,500 | 10,050 | 11,000 |
| Salaries and Commissions | 37,130 | 30,704 | 102,527 | 86,114 |
| Total operating expenses | 64,939 | 55,233 | 180,744 | 155,592 |
| Gross Income from operations | 44,043 | 47,114 | 142,636 | 144,452 |
| (EBITDA) | 44,043 | 47,114 | 142,636 | 144,453 |
Statement of Stockholders' Equity & Cash Flows (Sept 30, 2026 - Unaudited)
| Equity Statement | Series A Pref. | Common Shares | Stock Par ($) | Paid-in Capital ($) | Accum. Deficit ($) | Total ($) |
|---|---|---|---|---|---|---|
| Balance June 30, 2026 | 6,600 | 126,803,624 | 126,803 | 8,585,964 | -6,789,501 | 1,970,616 |
| Period Activity / Net Income ($44,043) | — | 2,000,000 | 2,000 | 20,965 | -10,965 | 11,788 |
| Ending Balance Sept 30, 2026 | 6,600 | 128,803,624 | 128,803 | 8,606,929 | -6,800,466 | 1,982,404 |
| Cash Flows From Operating Activities (9 Months Ended Sept 30) | 2026 ($) | 2025 ($) |
|---|---|---|
| Net income (loss) | 142,635 | 144,453 |
| Stock-based compensation | 0 | 0 |
| NET CASH USED IN OPERATIONS | 142,635 | 144,453 |
| NET CHANGE IN CASH AND CASH EQUIVALENTS | 354 | 152,572 |
| CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD | 248,682 | 230,480 |
| CASH AND CASH EQUIVALENTS AT END OF PERIOD | 251,443 | 235,782 |
1) Issuer Profile & 2) Security Information
- Outstanding Common Stock: 128,803,624 as of June 30, 2026; 128,803,624 as of September 30, 2026.
- Corporate History & Standing: Incorporated in Nevada (1996, Active). Known as BrandQuest Development Group, Inc. from 2006 to 2009; changed name to Novus Acquisition & Development Corp. in May 2009.
- Regulatory Status: Not a Shell Company; No Change in Control; No SEC/FINRA trading suspensions or halts; No stock splits, dividends, or reorganizations in past 12 months; No bankruptcy or receivership in past 5 years.
- Principal Executive Office & Place of Business: 2665 South Bayshore Drive #220, Miami, FL 33131.
- Transfer Agent: Olde Monmouth Stock Transfer | 200 Memorial Parkway, Atlantic Highlands, NJ 07716 | Phone: 732-872-2727 | Email: matt@oldemonmouth.com.
| Security Class | Symbol / CUSIP | Par Value | Authorized | Outstanding (9/30/26) | Shareholders of Record |
|---|---|---|---|---|---|
| Common Stock | NDEV / 67011R20 | $0.001 | 200,000,000 | 128,803,624 | 2,049 |
| Series A Preferred | NDEV / 67011R205 | $0.001 | 6,600 | 6,600 | 1 |
| Series B Dividend Shares | None | $0.001 | 10,000,000 | 0 | 0 |
| Series C Convertible | None | $0.001 | 10,000,000 | 0 | 0 |
| Series D Preferred | None | $0.001 | 100,000,000 | 0 | 0 |
Security Rights Summary: Common stock carries one vote per share, no dividends, and no preemption rights. Series A Preferred (6,600 shares issued) holds voting rights equivalent to 66% of total voting power across all classes, does not receive dividends, and is non-convertible. Series B ($1.00 stated value, 1:2 common conversion), Series C ($5.00 stated conversion, 1:1 common conversion), and Series D (foreign exchange class) have 0 shares issued and no voting rights.
3) Issuance History & Promissory Notes
Opening Balance (1-Jun-20): Common: 107,803,624 | Preferred: 5,600
| Date | Type | Shares Issued | Class | Price | Recipient | Reason / Services | Status |
|---|---|---|---|---|---|---|---|
| 6/29/20 | New Issuance | 500,000 | Common | $0.001 | Tysadco Partners | Consulting Contract | Restricted |
| 3/15/21 | New Issuance | 4,000,000 | Common | $0.001 | Gary F. Labrozzi, CEO | Employment Contract (2 yrs) | Restricted |
| 3/15/21 | New Issuance | 100,000 | Common | $0.001 | Health Insurance Solutions | Bonus Incentive | Restricted |
| 3/15/21 | New Issuance | 500,000 | Common | $0.001 | Tysadco Partners LLC | Consulting Contract | Restricted |
| 3/15/21 | New Issuance | 750,000 | Common | $0.001 | Mark Kuban | Employment Contract | Restricted |
| 6/15/21 | New Issuance | 500,000 | Common | $0.001 | Tysadco Partners LLC | Consulting Contract | Restricted |
| 9/4/24 | New Issuance | 5,000,000 | Common | $0.001 | Joe Krivelow | Sales Bonus | Restricted |
| 9/4/24 | New Issuance | 7,000,000 | Common | $0.001 | Dr. James Myers | Consulting Contract | Restricted |
| 9/4/24 | New Issuance | 6,000,000 | Common | $0.001 | Gary F. Labrozzi | Employment Contract (3 yrs) | Restricted |
| 12/17/24 | New Issuance | 1,000,000 | Common | $0.001 | Dr. James Myers | Consulting Contract | Restricted |
| 10/24/25 | New Issuance | 2,000,000 | Common | $0.001 | Dr. James Myers | Consulting Contract | Restricted |
Ending Balance (9/30/26): Common: 128,803,624 | Preferred: 6,600.
Leak-Out Provisions: Restricted common shares issued to third-party service providers are governed by a Leak-Out Agreement restricting divestiture to a maximum of 15% of the common stock's trailing 30-day average daily trading volume (ADTV).
Promissory Note (Issued 06-2015): Outstanding Balance: $175,941 (Principal: $90,000; Accrued Interest: $85,941) due to Frank Labrozzi, CEO for Operating Capital. Carries no call provision, conversion feature, or fixed maturity date.
4) Issuer's Business, Products, and Services
Novus, a legal cannabis health insurance carrier, has built its national dispensary network and HMO-style insurance infrastructure since 2015. Through its wholly owned subsidiary, WCIG Insurance Service, Inc. (WCIG), a California-domiciled insurance entity with nationwide reciprocity, Novus offers risk and non-risk health policies covering dental, vision, hearing, telemedicine, and cannabis benefits. Novus utilizes a dual-platform infrastructure isolating the prescription drug plan from the cannabis distribution platform. Importantly, Novus does not touch nor profit from the cannabis plant itself.
Active States & Jurisdictions (21): Arizona, California, Colorado, Florida, Hawaii, Illinois, Maine, Maryland, Massachusetts, Michigan, Missouri, Nebraska, Nevada, New Mexico, New York, Ohio, Oklahoma, Oregon, Pennsylvania, Vermont, Washington D.C.
Value Proposition by Stakeholder
- Shareholders: Unburdened by hard inventory, manufacturing, delivery vehicles, or warehousing; owns insurance policy receivables and benefits from insurance Embedded Value (EV) metrics.
- Policyholders: Members spending ~$300/month save 30% to 45% ($1,800 to $2,338 annually). Premiums can be covered via Employer-Sponsored Health Plans and HRAs.
- Cannabis Verticals: Drives foot traffic, reimbursement, and precision 5-meter geo-fenced mobile advertising and cross-device retargeting.
Benefiting From The Latest Regulations
- a) Schedule III Reclassification & SAFE Banking Act of 2026: State-licensed medical cannabis and FDA-approved products were officially reclassified to Schedule III by the DEA effective April 28, 2026 (with 900+ medical dispensaries granted federal DEA registrations in late October 2026, and Trulieve uplisting to the NYSE in June 2026 as a medical-only entity). Meanwhile, the SAFE Banking Act of 2026 (S. 4942 / H.R. 9471) remains in committee.
- b) Federal Independence: Because Novus does not touch the plant and sells insurance policies state-by-state via its compliant Rx platform, federal legislative delays do not impact operations.
- c–j) Additional Regulatory Drivers: Compassionate Care Act workplace protections; Veterans Cannabis Use for Safe Healing Act (19M veterans); $50B State AG Opioid Settlement Framework diversion compliance; California recreational-to-medical tax migration; Authorize.net credit card processing; California SB 1186 expansion; 1-hour regional delivery integration; Workers' Compensation opioid diversion.
Strategic Distribution & Health Carrier Contracts (15,000+ Agents)
- I. Institutional & Enterprise Distribution: PRAM (Prescription Resource Asset Management); Go Enroll / Elevate Wellness (9,200+ clients, 4,500+ employers); Unique Insurance Concepts (UIC - 5,000+ corporate clients).
- II. Agency & Brokerage Scaling (MGA Models): Healthfield Solutions, LLC (2,600 agents, 250,000-client base); Compass Health (agent portal & policy pairing); Back 9 Insurance (comparative rating engine across 50+ carriers).
- III. Specialized Healthcare & Wellness Solutions: OneShare Health (ACA-exempt medical cost-sharing); Essential Benefits (MEC - ACA-compliant preventative coverage); Wellness 360 (white-label workplace wellness); National Life (via Compass Health).
Management Discussion & Analysis (MD&A)
- New Provider — Upscale (www.shopupscalecbd.com): Institutional-grade, broad-spectrum, THC-free formulations manufactured in an NSF GMP-compliant facility in Phoenix, AZ, holding the NSF Certified for Sport designation.
- Addressing the Affordability Gap: With over 6 million registered U.S. medical cannabis patients (HHS data, early 2026) facing state/local excise taxes often exceeding 35%, Novus delivers a 35% to 40% direct cost reduction on verified network purchases and a 15% to 17% tax burden reduction via POS medical necessity integration.
5) Issuer's Facilities
- Corporate offices at 2665 South Bayshore Drive, Suite 220, Miami, FL 33131, leased for $1,200 annually.
- Wholly owned subsidiary WCIG Insurance Solutions, Inc. (California-domiciled insurance entity with nationwide reciprocity), acquired in 2017 for $530,000 via 10 million shares of common stock.
6) Officers, Directors, and Control Persons
| Name | Affiliation | Residence | Shares Owned | Class | Ownership % | Note |
|---|---|---|---|---|---|---|
| Frank Labrozzi | Chairman / CEO | Miami, FL | 51,900,000 | Common | 45.66% | Individual |
| Frank Labrozzi | Chairman / CEO | Miami, FL | 6,600 | Series A Pref. | 100% | Individual |
| James Myers | Individual | Kansas City | 16,000,000 | Common | 12.6% | Individual |
| John McDonald | Individual | Dallas, TX | 9,576,535 | Common | 7.55% | Individual w/ Leak-Out |
| Andrea Lopez | Director | Phoenix, AZ | 2,000,000 | Common | 1.6% | Individual |
7) Legal/Disciplinary History & 8) Service Providers
- Legal/Disciplinary History (Items 1–6 & Material Litigation): None / No across all categories for the past 10 years; no pending material legal proceedings.
- Securities Counsel: Crone Law Group | 420 Lexington Ave Suite 2446, New York, NY 10170 | 646-861-7891 | info@cronelawgroup.com.
- Accountant & Investor Relations: Frank Labrozzi, CEO | Novus Acquisition & Development Corp., 2665 South Bayshore Dr., Miami, FL 33131 | 855-228-7355 | frank@ndev.biz / info@getnovusnow.com.
- Social Channels: Twitter: https://twitter.com/Novus_Stock | Facebook: https://www.facebook.com/MMJHealthPlan/.
9) Disclosure Preparation & 10) Issuer Certifications
Prepared in accordance with U.S. GAAP by Frank Labrozzi, CEO/CFO/Chairman.
Principal Executive Officer & Principal Financial Officer Certifications:
I, Frank Labrozzi, certify that: (1) I have reviewed this Disclosure Statement for Novus Acquisition & Development Corp. Interim Report for the reporting period ended September 30, 2026; (2) Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made not misleading; and (3) Based on my knowledge, the financial statements and other financial information included fairly present in all material respects the financial condition, results of operations, and cash flows of the issuer as of, and for, the periods presented.
Date: 11/8/2026 | Digital Signature: /s/ Frank Labrozzi (CEO & CFO)
Notes to Financial Statements (Notes 1 – 3)
Note 1 — Description of Organization & Basis of Accounting
- Organization: Incorporated in Nevada on Nov 11, 1996 (Shirazi Corp. → Surface Tech, Inc. in Jan 2003 → BrandQuest Development Group, Inc. in Sept 2006 → Novus Acquisition & Development Corp. in April 2009).
- Nature of Operations & Non-Plant-Touching Posture: Operates via wholly owned California-domiciled licensed subsidiary WCIG Insurance Services, Inc. d/b/a Novus Cannabis MedPlan ("NCM"). Strictly a health plan carrier and benefits administrator; does not cultivate, process, distribute, or sell cannabis. All revenues derive from member plan fees and insurance policy premiums.
- Basis of Accounting & Valuation: Accrual basis conforming to U.S. GAAP. Evaluates insurance intrinsic value via Net Asset Value (NAV) per share (Total Assets less Total Liabilities divided by Shares Outstanding) and Embedded Value (EV) 20x multiple methodology.
Note 2 — Going Concern & Revenue Recognition (ASC 944 / ASC 606)
- Going Concern & Estimates: Carries standard going concern notation since the 2006 PCAOB audit; prepared using management estimates under U.S. GAAP.
- Revenue Recognition & PAPR Framework: Recognizes revenue under FASB ASC Topic 944 (Financial Services—Insurance) and ASC Topic 606 (five-step performance obligation model). Policyholder premiums and monetized insurance contracts are recognized over the binding policy period. The Company retains 100% of policyholder premiums upon binding and structures provider network economics through its Premium-Aligned Provider Remittance ("PAPR") framework.
Note 3 — Related-Party Loans, Investments, Taxes & Pronouncements
- Related-Party Advances (ASC 850 / ASC 470): Unsecured working capital advances from the CEO totaling ~$90,000 principal (7.9% per annum interest, due on demand, no call provisions, fixed maturity, or conversion features).
- Marketable Securities (ASC 320, 321, 326): Accounts for equity and debt securities (AFS/HTM) and credit loss allowances under standard GAAP hierarchy.
- Income Taxes (ASC 740 / ASU 2023-09) & Non-280E Status: Because NDEV operates strictly as a health insurance carrier and does not touch the cannabis plant, it computes tax provisions under standard corporate deductibility rules and is not subject to IRC Section 280E. Federal NOL carryforwards are tracked under TCJA and IRC Section 382 guidelines with full valuation allowances maintained.
- Additional GAAP Policies: Fair Value Hierarchy (ASC 820 Levels 1–3); Expense Disaggregation evaluation (ASU 2024-03 / 2025-01); Prior Year Misstatement evaluation (ASC 250 / SAB 99 & 108 — none recorded); Business Combinations (ASC 805); Fair Value Option (ASC 825-10); Stock-Based Compensation (ASC 718); Earnings Per Share & NAV (ASC 260); Internal-Use Software Capitalization (ASC 350-40).
- Commitments & Stock Classifications: Executive employment agreements include a nine-year non-dilution clause for officers/directors and acceleration upon change of control. Series A Preferred (6,600 shares) is senior to common stock, carries a $1,000/share liquidation preference, is non-convertible, and holds 66% aggregate voting power.
14 Quarters FINANCIAL Highlights
Other Highlights
- Distribution Scale: 15,000+ agents via Tier-1 carriers, MGAs, and InsureTech platforms.
- Premium Remittance: Retains 100% of binding premiums and recognizes revenue via PAPR reimbursement.
- Network Expansion: Integrated Upscale CBD with NSF Sport formulations for leagues.
- Regulatory Independence: Operates without touching plants, avoiding federal regulation.
- Valuation Methodology: Uses NAV and Embedded Value, applying a 20x NAV multiple.
Cap Structure
As of September 30, 2026
| Authorized Shares: | 200 million | |
| Outstanding Shares: | 128,803,624 | |
| Float: | 30,948,730 | |
| Par Value: | $0.001 | |
| Restricted Shares: | 88,989,251 | |
| Quote: | Click Here |
| Filings: | Click Here |
| Pitch Deck: | Click Here |
| Past Press Releases | Click Here |
Novus Acquisition & Development Corporation (NDEV), operating as Novus Cannabis MedPlan®, has pioneered health insurance that covers both THC/CBD cannabis and traditional prescription drugs since 2015. This proprietary dual-coverage structure provides a financial moat, ensuring stable, recurring revenue for Novus and its in-network providers.
Revenue is generated from insurance premiums, giving policyholders access to medications via an online distribution platform. NDEV has a national reach through 15,000 agents/brokers and over 200 dispensaries.
1. Compliance & The “Ancillary” Advantage
Novus is a non-plant-touching technology and administrative platform. Because we do not handle or profit directly from the sale of cannabis, we are not subject to IRS 280E tax restrictions. Our core product is a federally compliant Prescription Drug Program (PDP); cannabis is integrated strictly as a “value-added” discount feature, de-risking the model for institutional investors and traditional banking.
2. Employer-Centric Customization
We empower HR departments to modernize health benefits without legal exposure. Novus provides the framework for companies to align corporate values with modern wellness needs, offering a compliant structure that integrates cannabis-inclusive policies into traditional employer-sponsored health plans.
3. Novus Cannabis RX: Hybrid D2C Platform
Our Direct-to-Consumer platform bridges traditional healthcare and the cannabis industry through a “hybrid” model:
Traditional PDP: A robust prescription drug plan for FDA-approved medications.
Value-Added Access: Exclusive, pre-negotiated discounts at a nationwide network of licensed dispensaries.
Digital Integration: A single, professional portal for both traditional pharmacy benefits and alternative wellness.
4. Strategic Market Expansion
Novus is the primary “on-ramp” for consumers transitioning from the legacy (unregulated) market to legal, lab-tested products. By targeting the untapped employer market and partnering with national insurance brokers, the Novus MedPlan is positioned as the definitive distribution solution for the mainstreaming cannabis economy.
Federal Regulation: A Model Optimized for Growth
Strategic Positioning & Tax Efficiency: Novus is engineered to thrive within the current regulatory landscape. As a non-plant-touching technology and administrative platform, we are structurally insulated from the punitive restrictions that impact cultivators and retailers. This allows Novus to maintain standard corporate tax deductions and a healthy, scalable bottom line.
Institutional-Grade Compliance: We operate as a “grown-up” player in the space, prioritizing rigorous adherence to federal financial standards. Novus maintains strict Anti-Money Laundering (AML) and Bank Secrecy Act (BSA) protocols. This commitment to high-level compliance ensures we remain “institutional-ready,” safeguarding our relationships with traditional banking partners and enterprise-level clients.
Legislative Catalysts as Growth Drivers: Rather than remaining unaffected by federal shifts, Novus is positioned to catch the wave of industry evolution. We view Cannabis Rescheduling (Schedule III) and the SAFER Banking Act as massive growth tailwinds. These milestones will lower the barrier for entry for Fortune 500 employers, triggering a surge in demand for the compliant, turnkey benefit solutions that only Novus provides.
Interstate Scalability: By utilizing a state-regulated insurance framework and a federally compliant Prescription Drug Program (PDP), Novus can scale efficiently across legal jurisdictions. We provide a federally defensible bridge between traditional healthcare and the cannabis industry, offering stability in an evolving market.
NDEV’s Answer to the Cannabis Capital Crisis
Cannabis INDUSTRY VULNERABILITY
- The $6 Billion Debt Crisis: The U.S. cannabis industry faces a severe financial bottleneck with expensive, hard-to-refinance debt coming due by the end of 2026.
- Dilution Threat: Inability to refinance on favorable terms will likely prompt lenders to convert debt into equity, forcing massive shareholder dilution across the sector.
NDEV Business Model Comparison
- Asset-Light Insurance: By operating strictly as a health insurance carrier and using an HMO-style business model, NDEV does not directly handle cannabis.
- Complete Insulation: This eliminates the need for extreme capital expenditures and protects shareholder equity.
Core Operational Infrastructure
The "Affordability Gap" & Schedule III Tailwinds
The DOJ Schedule III reclassification eliminates federal 280E taxes for dispensaries, while NDEV provides up to 45% discounts and 15%–17% effective tax reductions to combat high state consumer excise taxes
Corporate & Personal HSA Integration
Employer-Sponsored Health Plans and Health Reimbursement Accounts directly fund policy premiums and medical reimbursements.
Dual-Platform Compliance Firewall
NDEV’s proprietary dual-platform framework that programmatically isolates the medical prescription drug plan operations from the physical cannabis distribution ordering platform.
How Reimbursement Works?
Reimbursement derives from policy revenue, contractually channeled to the MSO via standardized service fees. Defined exclusive territories secure asset utilization, protecting economic rights and ensuring stable, non-dilutable cash flow for MSO infrastructure.
Contact Us
* Indicates Required Field
855-228-7355
We are available Monday - Friday 9:00 am - 5:00 pm (EST) Email: info@getnovusnow.com
Forward-Looking Statements and Disclaimer: All communications, including AI-generated avatars accessed via social media, emails, SMS text messages, and other channels, are generated exclusively by Novus Acquisition & Development Corp (NDEV). NDEV does not utilize third-party agencies for press releases or promotional content. All materials rely solely on verified, publicly available investor relations data. The information provided is for informational purposes only and does not constitute investment or financial advice, nor is it an offer to sell or a solicitation of an offer to buy any securities.